Empagliflozin as a new management strategy on outcomes in patients with type 2 diabetes mellitus
Patients with type 2 diabetes mellitus have an increased risk of cardiovascular (CV) complications. Although hyperglycaemia contributes to the pathogenesis of atherosclerosis and heart failure in these patients, glucose-lowering strategies did not have a significant effect on reducing CV risk, parti...
Guardado en:
Autores principales: | Vladimir V. Salukhov, Tatiana Y. Demidova |
---|---|
Formato: | article |
Lenguaje: | EN RU |
Publicado: |
Endocrinology Research Centre
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/df96db84249147979cbed089b1755da3 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Perspectives on reducing mortality attributed to acute myocardial infarction among patients with type 2 diabetes mellitus in multicenter randomized trials
por: Sergey V. Kakorin, et al.
Publicado: (2016) -
The effect of empagliflozin on the development of chronic heart failure after myocardial infarction according to a 12-month prospective study
por: Alexey A. Nekrasov, et al.
Publicado: (2019) -
Comparative evaluation of empagliflozin, canagliflozin and sitagliptin cardioprotective properties in rats with experimental type 2 diabetes mellitus
por: A. V. Simanenkova, et al.
Publicado: (2021) -
Empagliflozin: a new strategy for nephroprotection in diabetes
por: Anton Ivanovich Korbut, et al.
Publicado: (2017) -
Glycemia control and glucose-lowering therapy in patients with type 2 diabetes mellitus and cardiovascular disease (review of multicenter randomized trials)
por: Sergey V. Kakorin, et al.
Publicado: (2016)